Eating disorders: an overview of treatment responses and the potential impact of vulnerability genes and endophenotypes.
Anorexia nervosa (AN), bulimia nervosa (BN) and binge-eating disorder (BED) are the three main eating disorders. Antidepressants, antipsychotics, anticonvulsants, prokinetic agents, opiate antagonists, appetite suppressants, tetrahydrocannabinol, cyproheptadine, zinc and ondansetron have been tested, and are frequently associated with psychological treatment. Selective serotonin reuptake inhibitors have a proven efficacy in BN and binge eating disorder. Other treatments, such as atypical antipsychotics in AN, anticonvulsants in BN and BED, and naltrexone and ondansetron in BN, may be promising, but lack the appropriate trials. The development of genetic researches in eating disorders may help the clinician to choose the most appropriate treatment in forthcoming years, using genetic polymorphisms of vulnerability genes, those linked to endophenotypes, or genes implicated in the metabolism of the drug treatment.
Ramoz
Nicolas
N
1INSERM U675, Université Paris 7, IFR02, Faculté de Médecine Xavier Bichat, Paris, France.
Versini
Audrey
A
Gorwood
Philip
P
D001068:Feeding and Eating Disorders / Q000188:drug therapy* / Q000235:genetics* / Q000523:psychology; D020022:Genetic Predisposition to Disease / Q000523:psychology*; D006801:Humans; D010641:Phenotype; D016896:Treatment Outcome